Ground News

institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

targetedonc.com image

News from targetedonc.com

See all of targetedonc.com’s headline news. Compare how the top news stories are covered by left-wing and right-wing news sources.

We’ve aggregated 699 of targetedonc.com’s headlines and news stories over the past 3 months.

Ground News rates targetedonc.com’s media bias as unknown. . Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

Is targetedonc.com credible or reliable? Our Factuality score answers both of those questions. When it comes to targetedonc.com, we’ve assigned a Unknown factuality rating. Ratings are assigned by aggregating scores from Ad Fontes Media and Media Bias/Fact Check.

Information about targetedonc.com

Where is targetedonc.com located?targetedonc.com's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top targetedonc.com News

Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery - Merck & Co (NYSE:MRK)

Cancer · United States

Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery - Merck & Co (NYSE:MRK)

100% Center coverage: 2 sources

The U.S. Food and Drug Administration (FDA) on Friday approved Merck & Co Inc.’s (NYSE:MRK) Keytruda (pembrolizumab) for adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 (combined positive score of at least 1), as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent…See the Story

Next-Generation TKI Approved for Advanced ROS1-Positive Lung Cancer

Pharma · United States

Next-Generation TKI Approved for Advanced ROS1-Positive Lung Cancer

100% Center coverage: 2 sources

(MedPage Today) -- The FDA approved taletrectinib (Ibtrozi) -- a next-generation oral ROS1 tyrosine kinase inhibitor (TKI) -- for the treatment of adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC)...See the Story

Sasanlimab Plus BCG in BCG-Naive, High-Risk Non-Muscle Invasive Bladder Cancer: the Randomized Phase 3 CREST Trial

United States · United States

Sasanlimab Plus BCG in BCG-Naive, High-Risk Non-Muscle Invasive Bladder Cancer: the Randomized Phase 3 CREST Trial

100% Center coverage: 2 sources

Bacillus Calmette–Guérin (BCG) induction and maintenance (I+M) after transurethral resection of bladder tumor is standard of care (SOC) in high-risk non-muscle invasive bladder cancer (NMIBC). However, disease recurrence/progression occurs in approximately 40% of patients at 2 years, with unfavorable prognosis. Limited bladder-sparing therapeutic options exist, and no improvements to response durability have been observed in decades. CREST is a …See the Story

#Evolving Chronic Lymphocytic Leukemia Treatment The FDA Approval of BRUKINSAs Tablet Formulation

In a groundbreaking development for oncology therapeutics, BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235) announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of BRUKINSA (zanubrutinib) for all five previously sanctioned indications. Originally introduced to combat chronic lymphocytic leukemia (CLL), this recent approval not only enhances the accessibility of this treatment modality but a…Pharma · United States See the Story

Five-Year Data Show Sustained Efficacy of Zanubrutinib in CLL With High Response Rates

The data from the 5-year analysis of arm C validate and support the efficacy and safety of zanabrutinib for treatment-naïve patients with CLL/SLL harboring del(17p).Healthcare See the Story

Linvoseltamab/Bortezomib Shows Consistent Safety in Relapsed/Refractory Multiple Myeloma

Linvoseltamab plus bortezomib showed a manageable safety profile and 85% ORR in relapsed/refractory multiple myeloma, with few discontinuations.Read Article

Evaluating Neoadjuvant and Adjuvant Therapies and Benefits for MIBC

During a live event, Matthew Galsky, MD, discussed adjuvant and neoadjuvant treatment approaches for muscle-invasive bladder cancer.Maryland · Maryland Read Article

Exploring Clinical Trial Barriers in Food Deserts: A Study of Breast Cancer Patients

Living in food deserts, clinical trial deserts, and areas with high transportation vulnerability significantly lowers breast cancer clinical trial participation.Breast Cancer Read Article

Expanded Approaches Focus on Balancing Efficacy and Toxicity in NSCLC

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.Read Article

Bridging Health Care Gaps: Making Clinical Trials Accessible

Travel barriers and lack of local sites hinder clinical trial enrollment for underserved patients, and decentralizing trials is key to improving access, according to Mariam Eskander, MD, MPH.Maryland · Maryland See the Story

Cytoreductive Nephrectomy in the Era of Immunotherapy for Kidney Cancer

Hyung Kim, MD, discussed the PROBE trial, a trial in progress, for patients with advanced kidney cancer.Maryland · Maryland Read Article

Breaking News Topics Related to targetedonc.com